{"id":763,"date":"2021-01-14T08:43:09","date_gmt":"2021-01-14T08:43:09","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=763"},"modified":"2021-01-14T08:43:09","modified_gmt":"2021-01-14T08:43:09","slug":"06-jan-2021-ivermectin-12-mg-iv-regime-may-have-superior-efficacy","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/06-jan-2021-ivermectin-12-mg-iv-regime-may-have-superior-efficacy\/","title":{"rendered":"(06 Jan 2021) Ivermectin-12 mg IV regime may have superior efficacy"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos<\/p>\n<p>https:\/\/www.medrxiv.org\/content\/10.1101\/2021.01.05.21249131v1<\/p>\n<p class=\"\">ISRCTN40302986- a translational proof of concept (PoC) randomized, double blind placebo controlled, dose response, parallel group study of IV efficacy in RT &#8211; PCR proven COVID 19 positive patients. 62 patients were randomized to 3 treatment groups. (A) IV 6mg regime, (B)IV 12 mg regime (given Q84hrs for 2weeks) (C, control) Lopinavir\/Ritonavir. All groups plus standard of Care. The Days to COVID negativity [DTN] was significantly and dose dependently reduced by IV (p = 0.0066). The DTN for Control were, = 9.1+\/\u22125.2, for A 6.0 +\/\u2212 2.9, and for B 4.6 +\/\u22123.2. 2 Way repeated measures ANOVA of ranked COVID 19 + \/ \u2212 scores at 0, 84, 168, 232 hours showed a significant IV treatment effect (p=0.035) and time effect (p &lt;0.0001). IV also tended to increase SPO2 % compared to controls, p = 0.073, 95% CI &#8211; 0.39 to 2.59 and increased platelet count compared to C (p = 0.037) 95%CI 5.55 &#8211; 162.55 \u00d7 10<sup>3<\/sup>\/ml. The platelet count increase was inversely correlated to DTN (r = \u22120.52, p = 0.005). No SAE was reported. 12 mg IV regime may have superior efficacy. IV should be considered for use in clinical management of SARS-Cov-2, and may find applications in community prophylaxis in high-risk areas.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos https:\/\/www.medrxiv.org\/content\/10.1101\/2021.01.05.21249131v1 ISRCTN40302986- a translational proof of concept (PoC) randomized, double blind placebo controlled, dose response, parallel group study of IV efficacy&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/06-jan-2021-ivermectin-12-mg-iv-regime-may-have-superior-efficacy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(06 Jan 2021) Ivermectin-12 mg IV regime may have superior efficacy&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,4,16,1],"tags":[38],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/763"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=763"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/763\/revisions"}],"predecessor-version":[{"id":764,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/763\/revisions\/764"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=763"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=763"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=763"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}